9,286 Shares in GSK plc (NYSE:GSK) Acquired by M.E. Allison & CO. Inc.

M.E. Allison & CO. Inc. acquired a new stake in GSK plc (NYSE:GSK - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 9,286 shares of the pharmaceutical company's stock, valued at approximately $314,000.

A number of other hedge funds also recently made changes to their positions in GSK. FMR LLC boosted its position in GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company's stock valued at $1,185,885,000 after buying an additional 2,224,345 shares during the last quarter. Fisher Asset Management LLC lifted its stake in shares of GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company's stock worth $759,425,000 after acquiring an additional 870,449 shares in the last quarter. Clifford Capital Partners LLC boosted its holdings in GSK by 14.3% in the third quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company's stock valued at $16,747,000 after purchasing an additional 51,378 shares during the last quarter. Cerity Partners LLC grew its stake in GSK by 61.8% during the 3rd quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company's stock valued at $17,728,000 after purchasing an additional 165,556 shares in the last quarter. Finally, Natixis Advisors LLC increased its holdings in GSK by 20.0% during the 3rd quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company's stock worth $20,460,000 after purchasing an additional 83,433 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on GSK shares. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Monday, January 13th. Guggenheim downgraded shares of GSK from a "buy" rating to a "neutral" rating in a research report on Thursday, October 31st. Jefferies Financial Group cut shares of GSK from a "buy" rating to a "hold" rating and reduced their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft cut GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Seven analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $43.25.

GSK Stock Performance

NYSE GSK traded up $0.02 during trading hours on Monday, reaching $33.46. The company's stock had a trading volume of 3,930,425 shares, compared to its average volume of 2,865,091. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The business has a 50-day simple moving average of $34.02 and a 200 day simple moving average of $37.97. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92. The stock has a market cap of $69.34 billion, a PE ratio of 21.72, a PEG ratio of 1.44 and a beta of 0.63.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were given a dividend of $0.3928 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.57 annualized dividend and a dividend yield of 4.70%. This is a positive change from GSK's previous quarterly dividend of $0.38. GSK's dividend payout ratio is currently 96.10%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.